Paper6608979
Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease.
Langston JW and 1 other. Can J Neurol Sci, 1984. Cited by 261 papers, by iCite.
Cite this record
ConductScience Library. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease. Papers, record 6608979. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6608979
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Parkinson Disease, Secondary | Major topic |
| Pyridines | Major topic |
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | |
| Adult | |
| Carbidopa | |
| Drug Combinations | |
| Female | |
| Hallucinations | |
| Humans | |
| Levodopa | |
| Male | |
| Movement Disorders | |
| Parkinson Disease |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT02200887 | Sleep Homeostasis in Parkinson's Disease | Background |
Source ClinicalTrials.gov
Cited by58
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 261 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39095480 | Astrocyte-derived apolipoprotein D is required for neuronal survival in Parkinson's disease. | NPJ Parkinsons Dis | 2024 | https://conductscience.org/library/papers/39095480 | PubMed |
| 38791036 | Insights into Calpain Activation and Rho-ROCK Signaling in Parkinson's Disease and Aging. | Biomedicines | 2024 | https://conductscience.org/library/papers/38791036 | PubMed |
| 38167027 | Impact of NQO1 dysregulation in CNS disorders. | J Transl Med | 2024 | https://conductscience.org/library/papers/38167027 | PubMed |
| 36035617 | PINK1: Multiple mechanisms of neuroprotection. | Int Rev Mov Disord | 2021 | https://conductscience.org/library/papers/36035617 | PubMed |
| 35513611 | A genome on shaky ground: exploring the impact of mitochondrial DNA integrity on Parkinson's disease by highlighting the use of cybrid models. | Cell Mol Life Sci | 2022 | https://conductscience.org/library/papers/35513611 | PubMed |
| 35246670 | Inflammation and immune dysfunction in Parkinson disease. | Nat Rev Immunol | 2022 | https://conductscience.org/library/papers/35246670 | PubMed |
| 34181202 | Research Models of the Nanoparticle-Mediated Drug Delivery across the Blood-Brain Barrier. | Tissue Eng Regen Med | 2021 | https://conductscience.org/library/papers/34181202 | PubMed |
| 34130867 | Neuronal autophagy and mitophagy in Parkinson's disease. | Mol Aspects Med | 2021 | https://conductscience.org/library/papers/34130867 | PubMed |
| 33494262 | Genetic and Environmental Factors Influence the Pleomorphy of LRRK2 Parkinsonism. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/33494262 | PubMed |
| 32110706 | Transplantation in the nonhuman primate MPTP model of Parkinson's disease: update and perspectives. | Primate Biol | 2017 | https://conductscience.org/library/papers/32110706 | PubMed |
| 31754997 | The Role of Xenobiotics and Trace Metals in Parkinson's Disease. | Mol Neurobiol | 2020 | https://conductscience.org/library/papers/31754997 | PubMed |
| 31671557 | Animal Models for Parkinson's Disease Research: Trends in the 2000s. | Int J Mol Sci | 2019 | https://conductscience.org/library/papers/31671557 | PubMed |
| 30030679 | Prevention of progression in Parkinson's disease. | Biometals | 2018 | https://conductscience.org/library/papers/30030679 | PubMed |
| 29428995 | Dyskinesias and levodopa therapy: why wait? | J Neural Transm (Vienna) | 2018 | https://conductscience.org/library/papers/29428995 | PubMed |
| 29271898 | Cellular and Molecular Aspects of the β-N-Methylamino-l-alanine (BMAA) Mode of Action within the Neurodegenerative Pathway: Facts and Controversy. | Toxins (Basel) | 2017 | https://conductscience.org/library/papers/29271898 | PubMed |
| 29125979 | Synaptic plasticity may underlie l-DOPA induced dyskinesia. | Curr Opin Neurobiol | 2018 | https://conductscience.org/library/papers/29125979 | PubMed |
| 28963508 | Genetic elimination of dopamine vesicular stocks in the nigrostriatal pathway replicates Parkinson's disease motor symptoms without neuronal degeneration in adult mice. | Sci Rep | 2017 | https://conductscience.org/library/papers/28963508 | PubMed |
| 28412346 | Superoxide is the critical driver of DOPAL autoxidation, lysyl adduct formation, and crosslinking of α-synuclein. | Biochem Biophys Res Commun | 2017 | https://conductscience.org/library/papers/28412346 | PubMed |
| 28391443 | Non-human primate models of PD to test novel therapies. | J Neural Transm (Vienna) | 2018 | https://conductscience.org/library/papers/28391443 | PubMed |
| 28106099 | Nesfatin-1 protects dopaminergic neurons against MPP+/MPTP-induced neurotoxicity through the C-Raf-ERK1/2-dependent anti-apoptotic pathway. | Sci Rep | 2017 | https://conductscience.org/library/papers/28106099 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/6608979
GET https://conductscience.org/api/papers/v1/6608979/cited_by?page=2